A new £19m continuous manufacturing facility was announced today by healthcare company GSK, marking an important milestone in its long-standing partnership with Singapore’s Economic Development Board.
The investment will be GSK’s first in continuous manufacturing for Active Pharmaceutical Ingredients (API) across its global network and reinforces the company’s commitment to continuously look for ways to advance its manufacturing practices to get medicines to patients as quickly as possible. The new facility will produce one of GSK’s key respiratory API’s, a therapy…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login